Your annual CER update doesn’t match your PMCF findings

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

The manufacturer had two separate teams. One team managed post-market surveillance and PMCF execution. Another team handled the CER updates. They worked on different timelines. They used different data sources. And no one owned the synchronization between PMCF findings and CER conclusions.

This is not an isolated case. It reflects a systemic issue across the industry.

Under MDR Article 61 and Annex XIV Part B, the Clinical Evaluation Report must be updated throughout the lifecycle of the device. MDCG 2020-7 clarifies that this is not a one-time obligation. It is a continuous process. And PMCF is the primary mechanism that feeds new data into that process.

But the regulation does not specify how to synchronize the two documents. It does not describe the workflow. It does not define roles. It assumes that manufacturers will establish a coherent system.

Most do not.

Why PMCF and CER Drift Apart

The PMCF plan is typically written early in the lifecycle. It defines objectives, data sources, and timelines. The plan is approved by the Notified Body. It gets filed. And then it enters a cycle of execution.

Data collection begins. Complaints are logged. Literature reviews are conducted. Registry data is analyzed. Clinical investigations are initiated if needed. The PMCF report is drafted annually or at defined intervals.

Meanwhile, the CER sits in a different folder. It was written for certification. It was reviewed during the conformity assessment. It reflects the clinical data available at the time of submission. And it remains static until someone decides to update it.

The problem is that “someone decides” is not a process.

In many organizations, the CER update is triggered by external events. A Notified Body requests an update. A significant change occurs. A new indication is pursued. But the routine annual update based on PMCF findings often does not happen.

This creates gaps. The PMCF report contains findings that are never transferred to the CER. The CER continues to cite outdated literature. The benefit-risk profile in the CER does not reflect current post-market data. And when the Notified Body reviews the technical file, they see inconsistency.

What the Annual Update Workflow Should Look Like

The workflow starts with the PMCF report. This is the trigger. When the PMCF report is finalized, it must be reviewed not just for post-market surveillance, but specifically for CER impact.

The question is not “what did we learn?” The question is “what does this mean for the clinical evaluation?”

This requires a structured review. I recommend a simple three-column table that maps PMCF findings to CER sections. Column one lists the PMCF finding. Column two identifies the affected CER section. Column three describes the required action: update, revise, or no change.

For example, if the PMCF report identifies a new publication comparing your device to an alternative therapy, that finding affects Section 5 of the CER (state of the art). It may also affect Section 6 (clinical data appraisal) and Section 7 (benefit-risk analysis).

If the PMCF report documents a complaint trend that was previously unknown, that affects Section 7 (benefit-risk) and may require a revision of residual risks.

If the PMCF report shows stable performance with no new safety signals, that still requires documentation in the CER. The absence of new risk does not mean no update. It means the benefit-risk profile is confirmed, and that confirmation must be stated.

Once the mapping is complete, the CER is updated. The update may be minor. It may involve adding a paragraph to Section 5 referencing new literature. It may involve revising a table in Section 7 to reflect updated complaint rates.

Or the update may be substantial. If the PMCF data reveals a shift in clinical performance, a new adverse event pattern, or a change in the competitive landscape, the CER may require significant rewriting.

The scope of the update is not fixed. It depends on the data. But the process of deciding the scope must be systematic.

The Role of the PMCF Evaluation Report

MDCG 2020-8 introduces the concept of the PMCF Evaluation Report. This is not the same as the PMCF report. The PMCF report documents the data collected. The PMCF Evaluation Report analyzes that data in the context of the clinical evaluation.

Many manufacturers skip this step. They produce a PMCF report and assume that is sufficient. But the PMCF Evaluation Report is the bridge between PMCF execution and CER update.

It answers specific questions. Does the PMCF data confirm the clinical performance stated in the CER? Does it reveal new risks? Does it suggest that the state of the art has evolved? Does it support continued use of equivalent devices as the primary clinical data source?

Without this evaluation, the PMCF data remains descriptive. It does not become actionable for the CER.

I have seen technical files where the PMCF report is thorough, the CER is well-written, but the two documents are not connected. The PMCF report sits in the post-market surveillance folder. The CER sits in the clinical evaluation folder. And no document explains how the PMCF findings influenced the CER conclusions.

The Notified Body asks: “Your PMCF report mentions three new comparative studies. Why are they not cited in your CER?” The manufacturer has no answer. Because no one performed the evaluation step.

Timing and Ownership

The timing of the annual update is critical. It must align with the PMCF reporting cycle. If the PMCF report is finalized in March, the CER update should be completed by April or May. Not six months later. Not the following year.

Delayed updates create version control problems. The PMCF report references a CER version that no longer reflects current data. The next PMCF cycle begins before the previous CER update is complete. The documents fall out of sync.

This is not just a documentation issue. It affects decision-making. If the benefit-risk analysis in the CER is outdated, the risk management file may be based on incomplete information. If the state of the art section is not updated, the clinical strategy may miss important competitive developments.

Ownership is equally critical. Someone must be responsible for the synchronization. In most organizations, this is the Clinical Affairs Manager or the Regulatory Affairs Manager. But responsibility must be explicit. It must be documented in procedures. It must be part of annual planning.

I recommend a simple matrix that assigns ownership for each step. Who finalizes the PMCF report? Who performs the PMCF evaluation? Who updates the CER? Who reviews the updated CER? Who submits it to the Notified Body?

Each role must have a deadline. Each deadline must be linked to the previous step. And the entire workflow must be visible to management.

What Notified Bodies Look For

When a Notified Body reviews an annual CER update, they are checking for coherence. They compare the PMCF report to the CER. They look for findings in the PMCF report that should have triggered changes in the CER.

If the PMCF report documents new literature and the CER does not reference it, that is a deficiency.

If the PMCF report identifies a safety signal and the CER does not update the benefit-risk analysis, that is a deficiency.

If the PMCF report shows a change in clinical use patterns and the CER does not address implications for the intended purpose, that is a deficiency.

The Notified Body is not just checking documents. They are checking the quality system behind the documents. They want to see that the manufacturer has a process. That the process is followed. And that the outputs are consistent.

A well-synchronized CER and PMCF file signals that the manufacturer has control over their clinical evaluation. A disconnected file signals gaps in the quality system.

Building a Sustainable Workflow

The sustainable workflow has five steps. First, finalize the PMCF report. Second, perform the PMCF evaluation. Third, map PMCF findings to CER sections. Fourth, update the CER. Fifth, submit the updated CER to the Notified Body.

Each step should have a defined timeline. Each step should have a defined owner. And each step should produce a traceable output.

The PMCF report is the input. The updated CER is the output. The PMCF evaluation and the mapping table are the process controls.

This workflow does not require complex software. It requires discipline. It requires clarity on roles. And it requires management oversight.

In organizations where this workflow is established, the annual update is routine. It takes a few weeks. It produces consistent results. And it satisfies Notified Body expectations.

In organizations where this workflow is missing, the annual update is chaotic. It triggers last-minute rewrites. It produces inconsistent documents. And it generates deficiencies.

The difference is not technical competence. It is procedural maturity.

Final Considerations

The CER is not a static document. It is the clinical foundation of your technical file. It must reflect current knowledge. It must integrate post-market data. And it must be updated systematically.

PMCF is the mechanism that generates that data. But PMCF alone is not sufficient. The data must be evaluated. It must be mapped to the CER. And it must be integrated into the clinical evaluation conclusions.

This requires a workflow. A workflow that connects PMCF execution to CER maintenance. A workflow that assigns roles and deadlines. A workflow that produces traceable outputs.

Without this workflow, the CER drifts. It becomes outdated. It loses alignment with post-market reality. And it fails to support the ongoing conformity assessment.

The manufacturers who succeed under MDR are the ones who build this workflow early. Who treat it as a core process. And who monitor it continuously.

The annual update is not an administrative task. It is a clinical governance activity. And it should be treated accordingly.

In the next part of this series, I will address how to handle PMCF findings that challenge your original clinical evaluation. What do you do when the post-market data does not confirm your pre-market assumptions? That is where the real test begins.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.

Aligning CER and PMCF update cycles prevents regulatory gaps. See the full timeline in our guide on how often to update your CER under MDR.